Aciex Therapeutics has entered into a collaborative research agreement with Portola Pharmaceuticals that provides Aciex with exclusive rights to develop Portola’s small molecule dual Spleen Tyrosine Kinase (Syk)/Janus Kinase (JAK) inhibitors for ophthalmic indications. Portola’s library includes compounds with preclinical systemic data packages as well as earlier stage research compounds. The two companies will develop the drugs to treat topical ophthalmic diseases, including ocular allergy, dry...